

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/088,771	Art Unit:	tba
Filed:	March 19, 2002	Examiner:	tba
1 <sup>st</sup> Inventor:	KATO, Kaneyoshi	Allowed:	
For:	Melanin Concentrating Hormone Antagonist	Batch:	
Atty. Dkt. No.	2648 USOP	Paper No.:	

**CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

**USPS EXPRESS MAIL LABEL. No. EV 082675951 US**

**DATE IN: August 9, 2002**

**Itemized Papers/Items:**


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page X 2)
3. Response to Notice of Missing Requirements (1 page), Submission of CRF of Sequence Listing (7 pages), IBM PC/AT format disk containing the CRF of the Sequence Listing, and copy of Notification of Missing Requirements (2 pages).

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents  
Washington, D.C. 20231.

on this date, 8/9/02

Dated: 8/9/02

  
Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

Please type a plus sign (+) inside this box → ☐


PTO/SB/21 (08-00)


Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p>(to be used for all correspondence after initial filing)</p>	Applicati n Numb r	10/088,771	
	Filing Date	March 19, 2002	
	First Named Inventor	KATO, Kaneyoshi	
	Group Art Unit	tba	
	Examiner Name	tba	
Total Number of Pages in This Submission	14	Attorney Docket Number	2648 USOP

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Certificate of Express Mailing Sequence Listing IBM PC/AT format disk Copy of NMP
Remarks		The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark Chao, Ph.D., JD, Reg. No. 37, 293
Signature	
Date	9/9/02

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class <sup>EXPRESS</sup> mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 9/9/02		
Typed or printed name	Gail L. Winokur	
Signature		Date 9/9/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # EV 08267595145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6

Application No.:	10/088,771	Art Unit:
Filed:	March 19, 2002	Examiner:
1 <sup>st</sup> Inventor:	KATO, Kaneyoshi	Allowed:
For:	Melanin Concentrating Hormone Antagonist	Batch:
Atty. Dkt. No.	2648 USOP	Paper No.:

Response to Notice of Missing Requirements Under 35 USC §371

BOX PCT  
Commissioner for Patents  
Washington, D.C. 20231  
Sir:

In response to the Notice of Missing Requirements mailed July 16, 2002, Applicants respectfully submit, along with a copy of the Notice, a Substitute written Sequence Listing and a DOS Text CRF Sequence Listing file "2648USOP.txt" on the enclosed 3.5" IBM PC/AT computer disk.

The Examiner kindly is requested to correct the Attorney DOCKET NUMBER for the present application to read:


--2648USOP-- instead of [2468usop].

The undersigned hereby certifies that the CRF and the written Sequence Listing are the same in content. The Sequence Listing contains no new matter, corrections in formatting and the present Serial Number and Filing Date information have been updated.

Respectfully submitted,

Dated: September 9, 2002

(847)383-3372  
(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

**COPY**

UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/088,771	Kaneyoshi Kato	2648 2468 USOP

INTERNATIONAL APPLICATION NO.
-------------------------------


PCT/JP00/06375

I.A. FILING DATE	PRIORITY DATE
09/19/2000	09/20/1999

Mark Chao PhD JD  
 Takeda Pharmaceuticals North America  
 Suite 500  
 475 Half Day Road  
 Lincolnshire, IL 60069

CONFIRMATION NO. 2340

371 FORMALITIES LETTER




\*OC000000008450254\*

Date Mailed: 07/16/2002

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments



The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/088,771	PCT/JP00/06375	2468 USOP